1. Home
  2. NWS vs RPRX Comparison

NWS vs RPRX Comparison

Compare NWS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWS
  • RPRX
  • Stock Information
  • Founded
  • NWS 2012
  • RPRX 1996
  • Country
  • NWS United States
  • RPRX United States
  • Employees
  • NWS N/A
  • RPRX N/A
  • Industry
  • NWS Newspapers/Magazines
  • RPRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWS Consumer Discretionary
  • RPRX Health Care
  • Exchange
  • NWS Nasdaq
  • RPRX Nasdaq
  • Market Cap
  • NWS 19.1B
  • RPRX 15.6B
  • IPO Year
  • NWS N/A
  • RPRX 2020
  • Fundamental
  • Price
  • NWS $33.15
  • RPRX $35.64
  • Analyst Decision
  • NWS Strong Buy
  • RPRX Strong Buy
  • Analyst Count
  • NWS 7
  • RPRX 3
  • Target Price
  • NWS $38.28
  • RPRX $45.33
  • AVG Volume (30 Days)
  • NWS 1.5M
  • RPRX 4.1M
  • Earning Date
  • NWS 11-06-2025
  • RPRX 11-05-2025
  • Dividend Yield
  • NWS 0.60%
  • RPRX 2.47%
  • EPS Growth
  • NWS 345.01
  • RPRX 54.86
  • EPS
  • NWS 2.07
  • RPRX 2.32
  • Revenue
  • NWS $8,452,000,000.00
  • RPRX $2,305,243,000.00
  • Revenue This Year
  • NWS $4.80
  • RPRX $35.01
  • Revenue Next Year
  • NWS $3.74
  • RPRX $3.14
  • P/E Ratio
  • NWS $16.00
  • RPRX $15.33
  • Revenue Growth
  • NWS 2.42
  • RPRX 3.02
  • 52 Week Low
  • NWS $26.25
  • RPRX $24.05
  • 52 Week High
  • NWS $35.58
  • RPRX $38.00
  • Technical
  • Relative Strength Index (RSI)
  • NWS 48.69
  • RPRX 45.51
  • Support Level
  • NWS $31.56
  • RPRX $34.84
  • Resistance Level
  • NWS $34.07
  • RPRX $36.94
  • Average True Range (ATR)
  • NWS 0.70
  • RPRX 0.84
  • MACD
  • NWS -0.05
  • RPRX -0.09
  • Stochastic Oscillator
  • NWS 54.64
  • RPRX 48.79

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: